Data / Public companies / SIC 2836: Biological products, (no diagnostic substances) / Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.: revenue, net income and total assets from its latest annual report
Updated December 19, 2025. Source: SEC Financial Statement Data Sets, filing 0001104659-25-123264.
Outlook Therapeutics, Inc. reported revenue of $1.4 million, a net loss of $62.4 million and total assets of $18.6 million for the fiscal year ended September 30, 2025, in its annual report (10-K) filed with the SEC on December 19, 2025. It ranks 76th by revenue of 89 companies in SIC 2836, biological products, (no diagnostic substances).
The request: Watch Outlook Therapeutics, Inc. (CIK 1649989): each new SEC filing, with revenue and net income. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 1649989
- Industry
- SIC 2836, Biological products, (no diagnostic substances)
- Business address (city and state)
- Iselin, New Jersey
- Incorporated in
- Delaware
- Filer category
- Non-accelerated filer
- Fiscal year ends
- September 30
- Latest annual report
- 10-K filed December 19, 2025
- Annual and quarterly reports in the data
- 1 annual, 4 quarterly
Financials for the fiscal year ended September 30, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $1,413,535 | Not listed | Not listed | sec.gov |
| Operating income | $-67,061,666 | Not listed | Not listed | sec.gov |
| Net income | $-62,424,863 | $-75,366,714 | 17.2% | sec.gov |
| Total assets | $18,584,183 | $28,823,154 | -35.5% | sec.gov |
| Total liabilities | $50,771,844 | Not listed | Not listed | sec.gov |
| Stockholders' equity | $-32,187,661 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $8,083,085 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -4416.2%
- Revenue rank in SIC 2836
- 76th of 89
- Revenue rank in New Jersey
- 119th of 127
- Revenue rank among all companies in the data
- 4,089th of 4,486
Companies next to it by revenue in SIC 2836
Biological products, (no diagnostic substances), from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Dyadic International Inc | Jupiter, FL | $3.1 million | $-7,364,628 | $9.9 million | -11.6% |
| Aligos Therapeutics, Inc. | South San Francisco, CA | $2.2 million | $-24,193,000 | $88.5 million | -39.5% |
| Vitro Biopharma, Inc. | Denver, CO | $2.1 million | $-10,851,802 | $4.9 million | 10.8% |
| Humacyte, Inc. | Durham, NC | $2 million | $-40,833,000 | $116.4 million | Not listed |
| Scinai Immunotherapeutics LTD. | Jerusalem, Israel | $1.3 million | $-8,307,000 | $11.6 million | 99.2% |
| Inhibrx Biosciences, Inc. | La Jolla, CA | $1.3 million | $-140,055,000 | $146.5 million | 550% |
| Pluri Inc. | Haifa | $1 million | $-23,821,000 | $24.9 million | -24% |
| Prokidney Corp. | Winston-Salem, NC | $893,000 | $-68,986,000 | $335.6 million | 1,075% |
Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.